Posts by: Jose Marques Lopes, PhD

Jose Marques Lopes, PhD

February 5, 2019February 5, 2019

Phase 3 Trial of RG6042 Will Gauge Potential of Gene-silencing Approaches for Huntington’s, Other Diseases

News

The upcoming Phase 3 trial of RG6042 will test whether lowering the levels of a mutant form of huntingtin (mHTT) translates into functional, motor and cognitive benefits for people ... Read more

January 10, 2019January 10, 2019

Machine Learning Applied to EEG Data May Serve as Huntington’s Biomarker, Study Suggests

News

A method called quantitative electroencephalography (qEEG) enables the identification of Huntington’s gene carriers and could become a disease biomarker, according to a pilot study. The research, “EEG may serve ... Read more

January 3, 2019January 3, 2019

Huntexil Failed to Improve Motor Function of Huntington’s Patients in Phase 2 Trial

News

Although well-tolerated, the investigational treatment Huntexil (pridopidine) failed to improve motor functions in a year-long Phase 2 clinical trial of Huntington’s patients. The research, “Safety and efficacy of pridopidine in ... Read more

October 4, 2018October 4, 2018

Mutant Huntingtin and Neurofilament Light Protein Could be Biomarkers in Huntington’s, Study Suggests

News

Measuring concentrations of mutant huntingtin (mHTT) protein and another protein, called neurofilament light protein (NfL), can provide early and specific indications of Huntington’s-related changes, according to a new study. ... Read more

October 2, 2018October 2, 2018

Phase 1b Trial Will Test Nilotinib’s Safety, Tolerability in Huntington’s Patients

News

A Georgetown University Medical Center (GUMC) Phase 1b clinical trial is recruiting patients to test the safety and tolerability of a leukemia treatment called nilotinib in Huntington’s disease patients. ... Read more

September 24, 2018September 24, 2018

Roche Set to Start 2 Clinical Studies of Potential Huntington’s Therapy RG6042

News

Two new clinical studies of Roche’s investigational therapy RG6042 for Huntington’s disease (HD) are planned to start by the end of 2018 and will begin enrolling participants by early 2019. These ... Read more

August 9, 2018August 9, 2018

Laquinimod Fails to Improve Motor Function but Reduces Brain Atrophy in Phase 2 Huntington’s Trial

News

Immunotherapy candidate laquinimod failed to meet its primary objective of improving motor function in Huntington’s disease patients after 12 months of treatment in a Phase 2 clinical trial. However, it did ... Read more

July 18, 2018

Genes Involved in Inflammation, Cellular Structure May Be Therapeutic Targets in Huntington’s

News

Targeting specific genes involved in inflammation and cellular structure may be a therapeutic strategy to reduce protein clumps in patients with Huntington’s disease, according to researchers. Their study, “High-Throughput ... Read more

June 19, 2018June 19, 2018

Defective Protein in Huntington’s Linked to Heart Dysfunction in Mouse Study

News

A key protein in Huntington’s disease has damaging effects on heart function beyond the disease’s devastating neurological impact, according to researchers. Their study, “Cardiac mTORC1 Dysregulation Impacts Stress Adaptation ... Read more

April 26, 2018April 26, 2018

#AAN2018 – Potential Huntington’s Treatment Halts Loss of Brain Volume, Improves Metabolism, Study Finds

News

Treatment with investigational medication VX15/2503 halts disease-related loss of brain volume and improves its metabolic activity in Huntington’s disease patients, according to a Phase 2 clinical study. The research, “Clinical Development ... Read more

Pin It on Pinterest